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Abstract 
     Failure of the human host to elicit adequate immune responses to the adult Schistosoma 
haematobium worm      and continuous strong inflammatory responses to the eggs have been 
the main causes of bladder pathology in chronic Schistosomiasis.      Identification of 
susceptibility biomarkers for schistosomiasis-     associated bladder pathology is necessary      in 
order to detect genetic factors responsible for the infection and spread of the disease. The aim 
of this study was to identify candidate-biomarkers for susceptibility to schistosomiasis and its 
associated pathologies. A total of 371 adult participants, comprising 130 males and 241 
females from Eggua community, Ogun State, Nigeria, were randomly recruited into a cross 
sectional study from August 2012 to May 2014. They were screened for S. haematobium ova 
and bladder pathologies by microscopy and ultrasonography, respectively. Human host 
susceptibility to schistosomiasis and its associated bladder pathologies were determined by 
PCR genotyping of Interleukin (IL4 and IL13) genes, and glutathione-S-transferase (GSTT1 
and GSTM1) genes. The overall prevalence of S. haematobium in the population was 29.3% 
(108/369).  Bladder pathologies were observed in 32.3% (117/362) of the population. 
Polymorphisms in IL 4-590 and IL 13-1055 were observed in 24.1% and 9.3% schistosomiasis 
cases, respectively. The IL 13-1055 polymorphism      did not indicate susceptibility to 
schistosomiasis in males (OR 0.7, 95% CI 0.3-2.1) but a slight risk was found in females (OR 
1.1, 95% CI 0.7-1.7). Participants with GSTM1 and GSTT1 polymorphisms expressed elevated 
risks of bladder pathologies (OR = 4.3, 95% CI 2.0 - 9.2 and OR = 4.2, 95% CI 1.5 – 12.0, 
respectively),      with the pathology and schistosomiasis group having more GST 
polymorphisms than bladder pathologies. 
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Introduction 
Not less than 700 million persons are globally 
estimated to be infected with schistosomiasis 
and at least 206.4 million people required 
preventive treatment in 2016 (Yassir et. al., 
2017; WHO, 2018). Nigeria is one of the most 
severely affected countries in Africa, with 29 
million cases as at 2010 (Adenowo et. al., 
2015). Indeed, a recent meta-analysis of 
schistosomiasis prevalence studies in Nigeria 
shows that the prevalence in Nigeria varied 
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from 2-82.5% with a pooled prevalence of 
34.7% (Abdulkadir et. al., 2017). Chronic 
morbidity during urinary schistosomiasis 
develops as a result of schistosome eggs that 
lodge in the bladder causing extensive tissue 
damage (Wilson et. al., 2007). The response to 
egg deposition could lead to calcification of the 
urinary bladder, infection, stone formation and 
mucosal proliferation (Zaghloul, 2012). Chronic 
infection with Schistosoma haematobium has 
been reported as a possible risk factor in the 
aetiology of bladder cancer (European 
Association of Urology, 2016; Onile et. al., 
2016). 
 
The intensity of schistosomiasis is reportedly 
influenced by a      Schistosoma mansoni 1 (SM1) 
gene that is mapped to a region of chromosome 
5 in the 5q31–q33 that codes for proteins that 
are associated with regulation of the Th2 
response such as cytokines like Interleukin (IL)-
3, IL-4, IL-5, IL-9, and IL-13 and 
Immunoglobulin (Ig) E (Dessein et. al., 2001; 
Gatlin et. al., 2009; Mbanefo et. al., 2014). 
Gatlin et. al., (2009) in a univariate analysis 
reported a significant correlation between 
resistance to reinfection with Schistosoma 
mansoni and the heterozygous (C/T) IL-13 -
1055 genotype, any T allele in the Interferon 
(IFN)-c +874 genotype, and the heterozygous 
(C/T) in the IL-4 -590 genotype. Analysis of S. 
haematobium infection in Mali revealed that 
polymorphisms in the IL13 gene promoter at 
−1055 and −591 were associated with the rate 
of Schistosoma infection. The IL-13 alleles 
−1055C and −591A were preferentially 
transmitted to children with      10% highest 
infection rate, whereas −1055T was associated 
with the lowest infection levels (Kouriba et. al., 
2005). 
 
It is thought that schistosomes redirect the 
early cell-mediated immunity in infection to 
cytokines that would favour establishment of 
the infection. S. haematobium infection-     
associated bladder damage is closely linked to 
immune reaction to the parasite deposited egg 
in the bladder which eventually induces chronic 
inflammation-     related granulomatous injury. 
We propose that infected and re-infected 
persons are genetically directed to produce 
inappropriate cytokine responses that lead to 
the establishment of chronic infections.   
Decrease in the activity of the carcinogen-
metabolizing enzyme glutathione-S-transferase 
(GST) in human bladder cancer tissues have 
been associated with S. haematobium infection 
(Sheweita et. al., 2004). Somali et. al., (2003) 
and Yajie et. al., (2016) found that deficiencies 
in the GSTT1 gene confer an increased risk of 
bladder cancer. The inhibition of GST activity 
may enhance the effect of many environmental 
carcinogens such as N-nitrosamines, thereby 
reducing the capacity of detoxifying many 
endogenous compounds in the bladder (Yajie 
et. al., 2016). 
In Nigeria, most studies have focused on the 
epidemiology of S. haematobium infection 
(Adenowo et. al., 2015 and Abdulkadir et. al., 
2017), with limited information about the 
morbidity resulting from urinary schistosomiasis 
in adults (Nmorsi et. al., 2007; Ekwunife et. al., 
2009; Onile et. al., 2016) while information on 
schistosomiasis susceptibility and resistance 
factors are lacking. This study was aimed at 
genotyping polymorphisms in Interleukin (IL-4 
and IL-13) and GST (M1 and T1) genes and 
determining their association with genetic 
susceptibility to schistosomiasis and its 
pathologies.  
 
Materials and Methods 
The study design, area, methods and 
participants have been described previously 
(Onile et. al., 2016; Anumudu et. al., 2019). 
Briefly, a cross- sectional study was carried out 
from August 2012 to May 2014 in Eggua (Figure 
1), a rural agrarian community where S. 
haematobium infections are prevalent. Children 
and participants with human immunodeficiency 
virus (HIV) were excluded from the study 
because the main objective was to determine 
the effect of chronic urinary schistosomiasis on 










Figure 1: Map of Yewa North Local Government Area showing the study areas  
 
A total of 371 participants between the ages of 
30 and >60 years were drawn from the village 
as they convened at the community health 
Centre following the initial announcement by 
the community leader. This study was a 
continuation of previously published work by 
Onile et. al., (2016).  
1. Ethical considerations 
Ethical approval was obtained from the 
University of Ibadan and University College 
Hospital (UI/UCH) Ethical Committee and Ogun 
State Ministry of Health. Informed consent was 
obtained from each participant. 




Figure 2: Polymorphisms in IL4, IL13, GSTM1 and T1 in susceptibility to schistosomiasis and associated 
bladder pathologies. Abbreviations: SH- S. haematobium infected groups, PT- Bladder Pathology group, 
PS- group with combination of pathology and S. haematobium infection and NPS- No pathology and 
schistosomiasis (Control). GSTs- Glutathione-S-transferase, IL- cytokine Interleukin      . 
3. Parasitology 
Study volunteers provided blood (2 mL) by 
venipuncture and urine (for egg count) 
specimens. The urine samples were collected 
between 10:00am and 2:00pm for maximum 
egg yield and were processed for parasitological 
examination and egg count (as previously 
described (Onile et. al., 2017; Adebayo et. al., 
2017; Olayinka et. al., 2020). The urine 
sediment (obtained by centrifuging 10ml of 
sample at 5000 rpm for 5 minutes) was 
examined microscopically to identify 
Schistosoma haematobium ova characterised 
by the presence of a terminal spine. The eggs 
were counted and the intensity of infection 
classified as light if ≤50 eggs/10 mL of urine and 
heavy if >50 egg/10 mL urine were present 
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(Nmorsi et. al., 2007; Onile et. al., 2016). In 
addition to microscopy, detection of macro and 
microhaematuria (urinalysis) for 
schistosomiasis was also done as described in 
Onile et. al., (2017) 
4. Ultrasound and Pathology 
A blind ultrasound examination was carried out 
by a radiologist for each participant in the study 
and classification of bladder pathologies was as 
previously described (Onile et. al., 2016).   
5. DNA Extraction and 
Purification 
DNA was purified from the blood samples using 
Thermos Scientific GeneJET Whole Blood 
Genomic DNA purification kit (Lithuania), 
following the manufacturer’s instructions. DNA 
concentration was measured by 
spectrophotometry. Aliquots (10 µL) of all 
samples was taken and subsequently adjusted 
to provide standard stock solutions of 20ng/µL. 
The A280/A260 ratio was estimated to provide 
an indication of the quality of the sample. Only 
samples that provided a yield of >20 ng/µL and 
A280/A260 ratio >1.8 and <1.95 were included 
for genotyping analysis. 
1. Genotyping for IL 4 
and IL 13 Genes  
PCR for IL-13 and IL-4 Single nucleotide 
polymorhisms (SNPs) was performed for 108 
samples from the participants that tested 
positive for urinary schistosomiasis by 
microscopy, using modifications from the 
original methods (references in Table 1), which 
enhanced optimal amplification.  
PCR for IL-13 -1055 C/T was conducted in a 25 
µl reaction mixture containing 100 ng DNA.      
Initial denaturation was performed at 95oC for 
3 min followed by 30 cycles of PCR with the 
following conditions: 95oC for 30 sec, 62oC for 
30 sec for annealing, 72oC for 1min for 
amplification, and a final extension at 72oC for 
3 min. This was done using the Hot Start Taq 
2X Master Mix (M0496L, BioLabs, New 
England). 
PCR for IL-13 -591 A/G was conducted in a 25 
µL reaction mixture containing 100 ng DNA and 
was done using the Hot Start Taq 2X Master Mix 
(M0496L, BioLabs, New England). Initial 
denaturation was performed at 94oC for 5 min 
followed by 30 cycles of PCR with the following 
conditions: 94oC for 1 min, 61oC for 45 sec for 
annealing, 72oC for 45 sec for amplification, and 
a final extension at 72oC for 3 min.  
PCR for IL-13 +130 G/A was conducted in a 25 
µL reaction mixture containing 100 ng DNA and 
the PCR reaction was done using the Hot Start 
Taq 2X Master Mix (M0496L, BioLabs, New 
England). Initial denaturation was performed at 
94oC for 5 min followed by 34 cycles of PCR with 
the following conditions: 94oC for 1 min, 60oC 
for 45 sec for annealing, 72oC for 45 sec for 
amplification, and a final extension at 72oC for 
3 min.  
PCR for IL-4 -590 C/T was conducted in a 25µL 
reaction mixture containing 100 ng DNA, using 
the Hot Start Taq 2X PCR Master Mix (M0496L, 
BioLabs, New England). Initial denaturation 
was performed at 95oC for 5 min followed by 30 
cycles of PCR with the following conditions: 
94oC for 30 sec, 59oC for 30 sec for annealing, 
72oC for 30 sec for amplification, and a final 
extension at 72oC for 3 min. 21 Purified PCR 








Figure 3: Identifying polymorphisms in IL4 509 T/C sequence, sense strand from Eggua 
 
6. GSTM1 and GSTT1 
Genotyping 
A total of 219 samples were genotyped for GST 
polymorphisms; these included 118 urinary 
tract pathology and 101 control cases. The 
control cases were randomly selected from 
among participants. The genotypes GSTM1-null 
and GSTT1-null, produced no GSTM1 and 
GSTT1 protein and consequently completely 
lack GSTM1 and GSTT1 enzymatic activity 
(Matic et. al., 2016). 
1. Genotyping for GSTM1 
Polymorphism 
This reaction was used to distinguish between 
GSTM1-active and GSTM1-null individuals. Two 
primers (G1 and G2) were used to amplify 
GSTM1 complementary DNA sequences 
(Brockmoller et. al., 2000). The G1 and G2 
amplified a 500-     base pair (bp) product 
specific for the GSTM1 gene. The presence of a 
GSTM1-null polymorphism was concluded from 
the absence of the specific 500-base pair 
fragment. 5μL DNA was amplified in a final 
volume of 25µL amplification reaction of 30 
cycles, using the Hot Start Taq 2X Master Mix 
(M0496L, BioLabs, New England) according to 
the manufacturer’s instructions.                                             
2. Genotyping for GSTT1 
Polymorphism  
The 25 µL volume amplification reaction for 
GSTT1 gene was done in a duplex PCR assay 
with a Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) primers used as 
internal control, for determination of GSTT1 
and GSTT1-null genotype. A 5 μL DNA template 
was amplified in a final volume of 25 µL 
amplification reaction of 30 cycles, using the 
Hot Start Taq 2X Master Mix (M0496L, BioLabs, 
New England) according to the manufacturer’s 
instructions.  
 
Table 1: The sets of primers used to genotype for IL 4 and IL 13 polymorphisms in the study 
S/
N 
Primer Name  Primer Sequence Reference  




Saric et. Al., 2008  
 
 
   
Reverse 5ʹ-CCAGTCTCTGCAGGATCAACC- 3ʹ 
2 IL13 -591 A/T Forward    5ʹ-
CCAGCCTGGCCCAGTTAAGAGTTT-3ʹ 
Reverse 5ʹ-CTAATTCCTCCTTGGCCCCACT- 3ʹ 
3 IL13 +130 G/A Forward 5ʹ- TGGCGTTCTACTCACGTGCT-3ʹ 
Reverse 5ʹ-CAGCACAGGCTGAGGTCTAA- 3ʹ 
4 IL4 -590 C/T Forward   5ʹ- ACTAGGCCTCACCTGATACG-3ʹ Gatlin et. al., 2009 
Reverse    5ʹ- GTTGTAATGCAGTCCTCCTG-3ʹ 
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5 GSTM1 G1: 5ʹ-CTGCCCTACTTGATTGATGGG- 3ʹ Brockmoller et. al., 
2000 G2: 5ʹ-CTGGATTGTAGCAGATCATGC -3ʹ 




  23 
Reverse: 5ʹ- ACG TCC TCT TGT CCC CCA TTC- 
3ʹ 
7 GAPDH Forward: 5ʹ- CAA AGC TTG TGC CCA GAC 
TGT- 3ʹ 




Statistical analysis was done using SPSS version 
20.0 to determine the χ2 and Odds ratio with P 
value set at <0.05. 
2. Results 
1. Prevalence of urinary 
schistosomiasis and bladder pathology 
A total of 371 participants (130 males and 241 
females) aged 30-90 years were recruited for 
the study. While 369 were eventually screened 
for S. haematobium infection and 362 for 
bladder pathologies, some of the volunteers 
were excluded from the study using the 
exclusion criteria (Table 2). The mean age of 
the participants was 48.6 ±0.6 years. The 
overall prevalence of S. haematobium in the 
sampled population was 29.3% (108/369), 42 
(11.4%) in males and 66 (17.9%) in females 
(Table 2). The Eggua community had the 
highest prevalence of infection 58 (16.0%), 
while Ibeku 9 (2.5%) had the least prevalence 
of infection (Table 2). Bladder pathologies were 
observed in 32.3% (117/362) of sampled 
population (Table 2).  
 
Table 2: Prevalence of Schistosomiasis among the settlements in Eggua  
 
 
      Villages 














Iganalade 10 (2.8) 27 (7.5) 37 (10.2) 27.0 Severe 8 (2.21) 
Agbon-Ojodu 31(8.6) 56 (15.5) 87 (24.0) 35.6 Total 117 (32.3) 
Ibeku 9 (2.5) 18 (5.0) 27 (7.5) 33.3   
Tata 0(0.0) 4 (1.1) 4 (1.1) 0   




Light Heavy Male Female   
28 (7.5) 80 (21.8) 42 (11.4) 66 (17.9)  
2.  
3. Cytokine gene polymorphisms 
and genetic susceptibility to schistosomiasis  
None of the S. haematobium infection cases 
was amplified for IL 13 +130 and IL 13 -591 
gene polymorphisms while genetic 
polymorphisms in IL 4 -590 and IL 13 -1055 
were      found in some of the      infected 
participants. IL 4 -590 and IL 13 -1055 were 
amplified and found to have      200bp and 
230bp, respectively. Majority (4 (40%) IL13-
1055 and 11 (42.3%) IL4-590) of the cytokine      
polymorphisms clustered around Eggua central 
among the understudied settlements (Table 3). 
 
 




Table 3: Distribution of cytokine polymorphisms across settlements in Eggua  
       
Villages 
IL 13 -1055 C/T  
Total 
N (%) 













4 (40.0) 25 (25.5) 29 (26.9) 
 
11 (42.3) 18 (22.0) 29 (26.9) 
Iganalade 2 (20.0) 17 (17.3) 19 (17.6)  4 (15.4) 15 (18.3) 19 (17.6) 
Agbon 
Ojodu 
3 (30.0) 21 (21.4) 24 (22.2) 
 
3 (11.5) 21 (25.6) 24 (22.2) 
Ibeku 1 (10.0) 18 (18.4) 19 (17.6)  1 (3.8) 18 (22.0) 19 (17.6) 
Tata 0 (0.0) 17 (17.3) 17 (15.7)  7 (26.9) 10 (12.2) 17 (15.7) 
Total 10 (100.0) 98 (100.0) 108 (100.0)  26 (100.0) 82 (100.0) 108 (100.0) 
 
 
Only 10 samples from the infected participants 
(9.3%) amplified for IL 13 -1055 polymorphism 
when analyzed for genetic susceptibility to 
schistosomiasis, and this showed no risk of 
infection in males 3 (7.5%) (OR 0.7, 95% CI 
0.3-2.1) and slight risk in females 7 (10.3%) 
(OR 1.1, 95% CI 0.7-1.7). Among 26 (24.1%) 
S. haematobium-     infected participants with IL 
4 -590 polymorphism     , a slight risk of infection 
was found both in male 10 (25%) (OR 1.05, 
95% CI 0.5-01.8) and female 16 (23.5%) (OR 
1.05; 95% CI 0.5-01.8) participants (Table 4). 
 
 




N (%) Male N (%) Female N (%) 
IL 4 
χ2 = 0.03, df= 1, P= 1.0 
   
S. haematobium 
Positive 
IL 4 -590 C/T 
Present 10 (25.0) 16 (23.5) 26 (24.1) 
Absent 30 (75.0) 52 (76.5) 82 (75.9) 






0.97 (0.7-1.4)  
IL 13 
χ2 = 0.23, df= 1, P= 0.74 
    
S. haematobium 
 
IL 13 -1055 
C/T 
Present 3 (7.5) 7 (10.3) 10 (9.3) 
Absent 37 (92.5) 61 (89.7) 98 (90.7) 
OR 
(95% CI) 
0.7 (0.3-2.1) 1.1 (0.7-1.7)  
 
4. GST gene      polymorphisms in 
susceptibility to schistosomiasis-     associated 
bladder pathologies 
Amplification of GSTM1 and GSTT1 genes 
yielded 500bp and 400bp fragments, 
respectively, among the sampled population. 
The GSTMI amplicons were found in 36 
(30.8%) pathology cases and 7 (7.1%) control 
samples while GSTT1 was found in 20 (17.1%) 
pathology cases and 4 (4.1%) control samples. 
Most of the participants with bladder 
pathologies had GSTM1 81 (69.2%) and GSTT1 
97 (82.9) null genotypes, respectively. These 
revealed an elevated risk of bladder pathologies 
for participants carrying either the GSTM1 (OR= 
4.3, 95% CI 2.0-9.2) or      GSTT1 (OR= 4.2, 
95% CI 1.5-12) polymorphic null genotype      
when compared to those with the 
corresponding genotype. However there were 
wide confidence intervals (Table 5).  
 
Table 5: Association between GSTT1 and GSTM1 polymorphisms and bladder pathology risk among the      
participants 





























P   
2 
tailed 
GSTM1         
Active 36 (30.8) 7 (7.1) 1.00ref 0.001 34 (30.2) 2 (30.0) 1.00ref 1.00 
Null 81 (69.2) 91 (92.9) 4.3 (2.0-9.2)  74 (69.8) 6 (70.0) 1.0 (0.4-2.7)  
GSTT1         
Active 20 (17.1) 4 (4.1) 1.00ref 0.002 18 (16.5) 2 (20.0) 1.00ref 0.63 
Null 97 (82.9) 94 (95.9) 4.2 (1.5-12)  91 (83.5) 6 (80.0) 0.8 (0.2-3.1)  
Combined Genotype         
Both Active 7 (6.0) 0 (0) 1.00ref 0.1 7 (6.6) 0 (0) 1.00ref 0.49 
Either 
Active 
42 (35.9) 11 (11.2) 3.4 (1.9-6.2)  36 (34.0) 4 (50.0) 0.7 (0.4-1.4)  
Both Null 68 (58.1) 87 (88.8) 0.6 (0.6-0.8)  63 (59.4) 4 (50.0) 1.2 (0.7-2.4)  
aConfidence Interval, bodds ratio, ref-Reference 
 
The risks associated with combined activities of 
the GSTM1 and GSTT1 genes were also 
examined and a higher risk of having bladder 
pathology was found in participants with one of 
either of the active genes (OR= 3.4, 95% CI 
1.9-6.2) compared to      those having both null 
genotypes (OR= 0.6, 95% CI 0.6-0.8). There 
was no distinctive risk found in having a high 
intensity of pathology with any of the GST 
genotypes when the combined variant and 
active genotype were considered, but there was 
a slight risk of mild bladder pathology in the 
participants in the presence of both inactive 
variants (both null genotype) when compared 
to those with either one alone (OR= 1.2, 95% 
CI 0.7-2.4).  
     Association of schistosomiasis and smoking 
in the development of bladder pathology 
among the participants was examined within 
the genotypes. It showed that the S. 
haematobium-     infected participants had more 
variant GSTM1 73.1% (OR= 1.7, 95% CI 1.0-
3) and GSTT1 85.9% (OR= 1.5, 95% CI 0.7-
3.1) null polymorphisms, revealing a slight risk 
of bladder pathology (Table 6). The case was 
different among smokers with null genotype for 
the GSTM1 and GSTT1 genotypes with higher 
risk of bladder pathology (OR= 3, 95% CI 1-7, 
P= 0.05; OR= 4, 95% CI 1-11, P= 0.006 
respectively).  
There was a slight risk of bladder pathology 
among the smokers and S. haematobium-     
infected participants with GSTT1 and GSTM1 
null polymorphisms (Supplementary Table 1).   
 
 
Supplementary Table 1: Relative risk estimates of bladder pathology associated with smoking and S. 
















Cigarette Smoking     
GSTT1      
Smokers Active 6 (40.0) 0 (0) 1.0ref 0.4 
 Null 9 (60.0) 2 (100) 1.2 (0.9-1.6)  
Non Smokers Active 14 (13.7) 4 (4.2) 1.0ref 0.02 
 Null 88 (86.3) 92 (95.8) 1.6 (1.1-2.1)  
GSTM1      
Smokers Active 7 (46.7) 0(0.0) 1.0ref 0.48 
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 Null 8 (53.3) 2 (100) 1.3 (0.9-1.7)  
Non-smokers Active 29 (28.4) 7 (7.3) 1.0ref 0.001 
 Null 73 (71.6) 89 (92.7) 1.8  
      
S. haematobium Infection     
GSTT1      
Positive Active 10 (16.4) 1 (5.9) 1.0ref 0.43 
 Null 51 (83.6) 16 (94.1) 1.2 (0.9-1.5)  
Negative Active 10 (18.2) 3 (3.7) 1.0ref 0.007 
 Null 45 (81.8) 78 (96.3) 2.1 (1.4-3.1)  
GSTM1      
Positive Active 20 (32.8) 1 (5.9) 1.0ref 0.02 
 Null 41 (67.2) 16 (94.1) 7.8 (0.9-63.1)  
Negative Active 15 (27.3) 6 (7.4) 1.0ref 0.002 
 Null 40 (72.7) 75 (92.6) 4.6 (1.7-13.0)  
aConfidence Interval,  bodds ratio, ref- Reference 
 
These risks were significant among non-
smokers with GSTT1 (OR= 1.6, 95% CI 1.1-2.1, 
P= 0.02) and GSTM1 (OR= 1.8, 95% CI 1.4-
2.2, P= 0.001) null genotypes in the population 
studied. Participants with or without S. 
haematobium infection having the null GSTT1 
and GSTM1 genotype also had a relatively small 
elevation in risk while some differences in the 
magnitude of risk associated with S. 
haematobium infection were apparent between 
the variants of the GSTM1 genotype (OR 7.8, 
95%CI 0.9-63.1, P= 0.02). Using multivariate 
analysis, it is evident in this study that bladder 
pathology has a statistically significant 
association with Schistosoma infection (F 
(1,205) =33.04; p=0.001; partial ƞ2=0.14), 
GSTM1 polymorphisms (F (1,205) =13.32; 
p=0.001; partial ƞ2=0.06) and cigarette 
smoking (F (1,205) =5.79; p=0.01; partial 
ƞ2=0.03). there was also statistically significant 
difference in bladder pathology and the studied 
risk factors (F (5,201) =11.42; p=0.001; Wilk’s 
A= 0.779, partial ƞ2=0.06) (Supplementary 
Table 2). 
 
Supplementary Table 2: Multivariate analysis showing the relationship between bladder pathology and 
gene polymorphisms among the participants 
 











Schistosoma Infection 6.637 1 6.637 33.035 0.000 0.139 33.035 
GSTM1 polymorphisms 1.775 1 1.775 13.324 0.000 0.061 13.324 
GSTT polymorphisms 0.318 1 0.318 4.259 0.040 0.020 4.259 
Combine Genotype for 
GSTs 
3.594 1 3.594 20.846 0.000 0.092 20.846 
Cigarette Smoking 0.334 1 0.334 5.787 0.017 0.027 5.787 




















Wilks' Lambda 0.779 11.419b 5.000 201.000 0.000 0.221 57.094 
 
3.  




1. Infection and Pathology  
The overall prevalence (29.3%) in      this study 
was higher than several reported cases in 
Nigeria (Nmorsi et. al., 2007; Dawet et. al., 
2012; Ugochukwu et. al., 2013; Olayinka et. al., 
2020). This could further explain the continuous 
and long-time exposure to infection and 
possibly contribute to S. haematobium subtle 
morbidity.  
The consistently higher frequency of light 
intensity of S. haematobium infection observed 
in this study as previously seen in Onile et. al., 
(2016) could be explained by some possible 
level of gradual development of acquired 
protected immunity by adults in this community 
due to chronic exposure to schistosomiasis 
(Barbosa et. al., 2006). Also, according to the 
WHO Expert Committee (WHO, 2002), 
prevalence and intensity of infection have been 
directly related to the patterns of variation with 
age with a reported decline in adults, an 
assertion supported by studies in Nigerian 
populations (Pukuma and Musa, 2007; Dawaki 
et. al., 2016). Pearce and MacDonald, (2002) 
also reported an obvious pattern of age-
dependent intensity of infection where those 
who are below the age of puberty carry the 
most parasites, and those in older age groups 
are generally less heavily infected.  
The association between S. haematobium 
infection and the presence of urinary tract 
abnormalities was consistent in our studies and 
similar to other previous reports (Nmorsi et. al., 
2007; Ekwunife et. al., 2009; Onile et. al., 2016; 
Serieye et. al., 1996). Also, S. haematobium 
infection has been associated with a two to 
tenfold increase in the risk of bladder squamous 
cell carcinoma, as well as being a potential 
cause of kidney damage (Driguez et. al., 2016). 
In fact, in some of the regions where S. 
haematobium is endemic, bladder cancer has 
been marked as the most common cancer in 
men and the second in women, just behind 
breast cancer, and accounts for as much as 
30% of all cancer cases (Botelho et. al., 2010). 
A meta-analysis of the estimated disease 
burden showed that morbidity and mortality 
attributed to schistosomiasis increases with 
DALYs (disability-adjusted life years) which had 
risen to about ~20% increase in the past 20 
years (Driguez et. al., 2016; Murray et. al., 
2013). A retrospective review of clinical records 
of bladder cancer cases in Sokoto, Nigeria 
between 1999 and 2004 showed a 4.7 fold rise 
in the number of bladder cancer cases, with 
squamous cell carcinoma composed of 65.1% 
of histologically verified cases and 50% of the 
squamous cell carcinoma showed evidence of 
chronic urinary schistosomiasis (Mungadi and 
Malami, 2007).  
 
Genetic Susceptibility to Schistosomiasis 
The presence of polymorphisms in cytokine 
genes IL 4-590 C/T and IL13-1055 C/T among 
the S. haematobium-     infected participants in 
this study was similar to findings from some 
previous studies (Kouriba et. al., 2005; Gatlin 
et. al., 2009; He et. al., 2008). Gatlin et. al., 
(2009) had reported more resistance to 
infection among men with a      combination of 
IL-13 21055 C/T and IL-4 2590 C/T genotypes 
when compared to      those seen with the sum 
of the separate effects of IL-13 21055 C/T and 
IL-4 2590 C/T on resistance. Other studies have 
shown a marked increase in the plasma levels 
of IL-5 and IL-13 in individuals identified as 
being resistant to schistosome infection 
(Leenstra et. al., 2006). Therefore, to 
understand the role of this heterozygous 
cytokine as a susceptibility or resistance factor, 
further post-     treatment follow-up study will 
be required among the infected      participants 
to establish the role of these cytokines as has 
been done in other similar studies (Cameron et. 
al., 2006; Gatlin et. al., 2009). Gatlin et. al., 
(2009) had reported that individuals with 
polymorphisms at positions IL-13 -1055 and IL-
4 -590 are more likely to require fewer 
reinfections and treatments to become resistant 
to reinfection than individuals who are 
homozygous at either position. Another study in 
Mali revealed an association between a single-
nucleotide polymorphism in the STAT6 gene at 
12q13.3 and intensity of infection by S. 
haematobium; this polymorphism had an 
additive effect with IL13 −1055 (He et. al., 
2008). 
Other analyses of S. haematobium infection in 
Mali revealed that in chromosomal region 5q31-
q33, polymorphisms in the IL13 gene promoter 
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at position −1055 and −591 were associated 
with the infection rate: alleles −1055C and 
−591A were preferentially transmitted to 
children with      10% highest infection rate, 
whereas −1055T associated with the lowest 
infection levels (Kouriba et. al., 2005).  IL4 
−590T allele has been associated with high IgE 
production,      thereby having increased 
resistance to infection (Russell et. al., 2015).  
Evidence has shown that imbalance in 
activation and detoxification by detoxifying 
enzymes (GSTs) due to gene polymorphisms 
may influence an increase in bladder cancer risk 
due to accumulation of carcinogen metabolites 
(McGrath et. al., 2006; Ying et. al., 2016; 
Jobaida et. al., 2016; Yajie et. al., 2016). 
Common polymorphisms occur in almost all 
members of GSTs (Ying et. al., 2016) and 
several types of allelic variations have been 
observed (Djukic et. al., 2013; Yajie et. al., 
2016; Matic et. al., 2016) which include GSTM1 
and GSTT1 class deletion polymorphism 
(GSTM1-null and GSTT1-null). The null 
genotypes produce no GSTM1 and GSTT1 
protein and consequently completely lack 
GSTM1 and GSTT1 enzymatic activity (Djukic 
et. al., 2013). 
In this study, GSTM1 and GSTT1 null 
polymorphisms were shown to significantly 
increase the risk of structural bladder 
pathology. This agrees with Arnaldo et. al., 
(2000),      Aktas et. al., (2001),      Cengiz et. 
al., (2007),      Yajie et. al., (2016) and Jobaida 
et. al., (2016) who also observed a risk of 
bladder cancer with GSTM1 and GSTT1 null 
polymorphisms. Okkels et. al., (1996) and 
Arnaldo et. al., (2000) reported that the 
association of GSTM1 null genotype with 
bladder tumour was more apparent in a      
group with less aggressive tumours, as      we 
also observed in this study. This could further 
support the presence of GSTM1 null genotype 
among the urinary tract pathology cases (an 
indicator of early stage of possible progression 
to bladder cancer). Among the bladder 
pathology cases, the distribution of the 
polymorphisms was relatively similar to the 
control group with slightly higher GSTM1 null 
genotype in the control cases. This is similar but 
considerably higher than what was reported in 
several other studies (Okkels et. al., 1996; 
Arnaldo et. al.,2000; Jobaida et. al., 2016). The 
role of GSTT1 null genotype in bladder cancer 
risk remains unresolved. Several studies 
suggested an increased risk (Moore et. al., 
2004; Yajie et. al., 2016; Jobaida et. al., 2016; 
Ying et. al., 2016), but others suggested no 
risks or low risks (Karagas et. al., 2005; 
McGrath et. al., 2006; Matic et. al., 2016). In 
the present study, an elevated risk of bladder 
cancer was found among the S. haematobium     
-     infected participants; and this was more in 
smokers with null GSTM1 and GSTT1 
polymorphisms. This finding is similar to those 
observed by Moore et. al., (2004) and Yu et. al., 
(2017) where elevated risk to bladder cancer 
was only seen in smokers with the GSTT1 null 
polymorphism and seems to buttress the 
observation that smoking is the most important 
risk factor for susceptibility to bladder cancer. 
2. Conclusion 
The prevalence of urinary schistosomiasis 
among adults is relatively high in the study area 
when compared with other areas in Nigeria. 
Individuals with bladder pathologies could have 
heavy or light intensity of schistosomiasis or 
have no existing infection at all. However, long 
term exposure to schistosomiasis is necessary 
for the development of bladder pathology which 
may eventually advance to cancer. IL 13-1055 
polymorphisms did not indicate susceptibility to 
schistosomiasis in males, but a slight risk was 
found in females. GSTM1 and GSTT1 
polymorphisms were associated with elevated 
risk of bladder pathology with the pathology 
and schistosomiasis group having more GST 
polymorphisms than the group with only 
bladder pathology.  
Limitation of the study 
In order to elucidate properly the role of GST 
(GSTM1 and GSTT1) polymorphisms in      
susceptibility to urinary schistosomiasis 
associated bladder pathology, it is important to 
conduct a repeat of this study with a much 
larger sample size. Also, molecularly 
characterized schistosomiasis negative control 
samples will be required to further establishe      
the relationship (susceptibility/resistance) 
between the cytokines (IL-13 -1055 and IL-4 -
590) and urinary schistosomiasis. 
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